Good afternoon :)
Sanjivani Paranteral Ltd

Sanjivani Paranteral Ltd

SANJIVIN Share Price

BSE
189.650.42% (-0.80)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹237 cr, stock is ranked 2,518

Stock is 4.17x as volatile as Nifty

SANJIVIN Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹237 cr, stock is ranked 2,518

Stock is 4.17x as volatile as Nifty

SANJIVIN Performance & Key Metrics

SANJIVIN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.894.67
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.425.910.50%

SANJIVIN Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

SANJIVIN Company Profile

Sanjivani Paranteral is engaged in the business of pharmaceutical products.

SANJIVIN Similar Stocks (Peers)

Compare with peers Compare with peers 

SANJIVIN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
39.76
39.76
1Y Return
21.68%
21.68%
Buy Reco %
93.55
93.55
PE Ratio
86.09
86.09
1Y Return
36.45%
36.45%
Buy Reco %
82.14
82.14
PE Ratio
29.83
29.83
1Y Return
11.97%
11.97%
Buy Reco %
62.86
62.86
PE Ratio
22.17
22.17
1Y Return
13.13%
13.13%
Buy Reco %
57.69
57.69
PE Ratio
18.88
18.88
1Y Return
9.44%
9.44%
Buy Reco %
51.52
51.52
Compare with Peers

SANJIVIN Sentiment Analysis

SANJIVIN Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

SANJIVIN Stock Summary · May 2026

Management framed FY'26 as a transition year and positioned FY'27 as a scale‑up phase, reporting consolidated Q4 revenue of INR 132.1 million and targeting base‑business revenue of INR 80–85 crore for FY'27. Leadership emphasized execution of a multi‑vertical strategy—expanding injectables, IV fluids and nutraceuticals through joint ventures and recent capacity additions—while highlighting early commercial traction from the new IV line and a ramping European nutraceutical JV. They struck a constructive, execution‑focused tone but acknowledged clear tensions: heavy export dependence combined with late‑February/March shipping disruptions materially reduced Q4 shipments, and near‑term input‑cost and packaging pressures have required elevated inventories and higher freight. Management described mitigation steps taken (alternative routing, supplier diversification, partial freight reimbursement) and noted receivables have shortened, improving working capital. Regulatory approvals remain a gating factor for commercial scale‑up and were delayed in some cases, but management said approvals and export execution should improve and they expect export revenues to recover in Q1 FY'27 as the company pursues the annual targets.

SANJIVIN Stock Growth Drivers
SANJIVIN Stock Growth Drivers
6
  • Established, quality‑focused manufacturing and broad export footprint

    The company is a WHO GMP–certified manufacturer with over 25 years of injectable and oral‑dosage

  • Strategic diversification into multiple verticals with early commercialization success

    Management has shifted the business model from a single‑engine to a multi‑vertical platform, executing joint

SANJIVIN Stock Challenges
SANJIVIN Stock Challenges
6
  • Logistics and supply‑chain disruptions causing lost exports and operational uncertainty

    Geopolitical tensions at the end of February disrupted shipping routes, container availability and cargo handling

  • Margin compression from higher input and logistics costs combined with lower operating leverage

    A combination of increased raw‑material and packing costs in March 2026, elevated freight from rerouted

SANJIVIN Forecast

SANJIVIN Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

SANJIVIN

SANJIVIN

Income

Balance Sheet

Cash Flow

SANJIVIN Income Statement

SANJIVIN Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue12.9216.5218.5217.6618.6117.9315.6622.3613.8123.99
Operating & Other expensessubtract10.7114.1015.2814.8015.5715.2413.2518.2211.6419.67
Depreciation/Amortizationsubtract0.240.130.150.160.180.160.170.230.660.65
Interest & Other Itemssubtract0.090.020.180.190.200.220.050.210.310.35
Taxes & Other Itemssubtract0.630.560.620.610.460.570.550.920.660.83
EPS1.081.471.961.621.841.461.332.210.492.03

SANJIVIN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

SANJIVIN Stock Peers

SANJIVIN Past Performance & Peer Comparison

SANJIVIN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sanjivani Paranteral Ltd35.514.67
Sun Pharmaceutical Industries Ltd39.765.440.84%
Torrent Pharmaceuticals Ltd86.0910.590.69%
Cipla Ltd29.833.350.91%

SANJIVIN Stock Price Comparison

Compare SANJIVIN with any stock or ETF
Compare SANJIVIN with any stock or ETF
SANJIVIN
Loading...

SANJIVIN Holdings

SANJIVIN Shareholdings

SANJIVIN Promoter Holdings Trend

SANJIVIN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SANJIVIN Institutional Holdings Trend

SANJIVIN Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SANJIVIN Shareholding Pattern

SANJIVIN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding31.56%0.00%5.45%0.00%62.98%

Sep 2025

Dec 2025

Mar 2026

Jun 2026

SANJIVIN Shareholding History

SANJIVIN Shareholding History

MarJunSepDec '25MarJun0.00%0.00%0.00%0.00%0.00%0.00%

SANJIVIN Insider Trades & Bulk Stock Deals

SANJIVIN Insider Trades & Bulk Stock Deals

Loading...

smallcases containing SANJIVIN stock

smallcases containing SANJIVIN stock

Looks like this stock is not in any smallcase yet.

SANJIVIN Events

SANJIVIN Events

SANJIVIN Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

SANJIVIN Dividend Trend

No dividend trend available

SANJIVIN Upcoming Dividends

SANJIVIN Upcoming Dividends

No upcoming dividends are available

SANJIVIN Past Dividends

SANJIVIN Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2025

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 19, 2025

SANJIVIN Stock News & Opinions

SANJIVIN Stock News & Opinions

Corporate
Corporate
Shareholders can vote electronically via InstaVote, contacting NSDL or CDSL for assistance

Shareholders are instructed to cast their votes electronically via the InstaVote platform, accessible at [https://instavote.linkintime.co.in/](https://instavote.linkintime.co.in/), utilizing either direct vote entry or file upload methods. Individual shareholders holding securities in demat mode should contact NSDL (evoting@nsdl.co.in or 022 - 4886 7000) or CDSL (helpdesk.evoting@cdslindia.com or 1800 22 55 33) for assistance with user ID or password recovery. Shareholders holding securities in physical mode or corporate shareholders experiencing issues with InstaVote can reach out to enotices@in.mpms.mufg.com or 022 – 4918 6000. Shareholders are reminded to keep their passwords confidential and that once a vote is cast, it cannot be altered.

1 week agoCapital Market - Live
Corporate
Corporate
Shareholders can vote electronically via NSDL, CDSL portals, or INSTAVOTE platform

Shareholders have multiple options for electronic voting, as detailed in the company’s annual report. Individual shareholders with Demat accounts can vote through the NSDL portal, contacting the helpdesk at evoting@nsdl.co.in or 022 - 4886 7000, or the CDSL portal, reaching the helpdesk at helpdesk.evoting@cdslindia.com or 1800 22 55 33. Shareholders holding physical shares or those with Demat accounts utilizing INSTAVOTE can access the platform at instavote.linkintime.co.in, while corporate shareholders have the option to enter votes directly or upload a prepared file, requiring a scanned copy of a Board resolution or Power of Attorney. General helpdesk support for INSTAVOTE is available at enotices@in.mpms.mufg.com or 022 – 4918 6000.

1 week agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral Ltd consolidated sales up 80.47% on year in Q2FY2026, net profit soared by 352.73%

Sanjivani Paranteral Ltd share price inched up 2.93% to Rs 191.45 after the company's net profit saw a strong growth of 352.73% to Rs 2.49 crore, while revenue from operations increased sharply by 80.47% to Rs 23.84 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.69%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Sanjivani Paranteral Ltd has slipped by 0.91% and 40.46% in the same period respectively. Profit before tax (PBT) of Sanjivani Paranteral Ltd stood at Rs 3.32 crore in Q2 FY26, rallying 44.35% year-on-year, and surging by 176.67% quarter-on-quarter. EBITDA came in at Rs 4 crore, expanding by 54.62% YoY and jumping 310.20% sequentially. Total expenses surged 65.34% to Rs 20.32 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 15.67 crore, witnessing a sharp rise of 110.34% YoY, while employee benefits expense was at Rs 2.35 crore, easing 4.91% YoY. For the TTM ended FY26, revenue from operations jumped by 28.84% to Rs 70.1 crore, while net profit jumped 31.12% to Rs 8.09 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 641% to Rs 9.13 crore, and PBT soared 36.72% to Rs 10.35 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 12.4 crore in FY26, as against Rs 10.7 crore in FY25. Sanjivani Paranteral Ltd crashed 9.99% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.

2 weeks agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral Limited to review financial results at a board meeting Friday

Sanjivani Paranteral Limited will hold a board meeting on Friday, August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, and the annual report for the financial year ended March 31, 2026, according to a regulatory filing with the BSE Limited.

3 weeks agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral to convene board meeting

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 23 July 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral to hold board meeting

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 21 May 2026.

3 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit declines 74.89% in the March 2026 quarter

Net profit of Sanjivani Paranteral declined 74.89% to Rs 0.55 crore in the quarter ended March 2026 as against Rs 2.19 crore during the previous quarter ended March 2025. Sales declined 27.34% to Rs 13.21 crore in the quarter ended March 2026 as against Rs 18.18 crore during the previous quarter ended March 2025. For the full year,net profit declined 17.31% to Rs 6.69 crore in the year ended March 2026 as against Rs 8.09 crore during the previous year ended March 2025. Sales declined 2.04% to Rs 68.67 crore in the year ended March 2026 as against Rs 70.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales13.2118.18 -27 68.6770.10 -2 OPM %11.8814.36 -15.0114.76 - PBDT1.862.84 -35 10.6110.97 -3 PBT1.202.65 -55 9.3910.35 -9 NP0.552.19 -75 6.698.09 -17 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral schedules board meeting

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 14 May 2026.

3 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit rises 46.32% in the December 2025 quarter

Net profit of Sanjivani Paranteral rose 46.32% to Rs 2.78 crore in the quarter ended December 2025 as against Rs 1.90 crore during the previous quarter ended December 2024. Sales rose 27.15% to Rs 22.06 crore in the quarter ended December 2025 as against Rs 17.35 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales22.0617.35 27 OPM %17.3614.70 - PBDT3.932.67 47 PBT3.702.51 47 NP2.781.90 46 Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral to announce Quarterly Result

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live

6 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. The share price of SANJIVIN as on 4th September 2026 is ₹189.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Sanjivani Paranteral Ltd (SANJIVIN) share are
    • Past 1 week: 1.06%
    • Past 1 month: 14.46%
    • Past 3 months: 32.53%
    • Past 6 months: 9.67%
    • Past 1 year: -23.54%
    • Past 3 years: 109.26%
    • Past 5 years: 563.59%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd (SANJIVIN) is ₹237.58 Cr as of 4th September 2026.

  4. The 52-week high of Sanjivani Paranteral Ltd (SANJIVIN) is ₹268 and the 52-week low is ₹126.

  5. The P/E (price-to-earnings) ratio of Sanjivani Paranteral Ltd (SANJIVIN) is 35.51. The P/B (price-to-book) ratio is 4.67.

  6. Sanjivani Paranteral Ltd (SANJIVIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  7. You can directly buy Sanjivani Paranteral Ltd (SANJIVIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.